Relmada Therapeutics, Inc.
看多

Jefferies initiated Relmada Therapeutics with buy $75 target

291
Jefferies analyst Andrew Tsai initiated coverage of Relmada Therapeutics with a Buy rating and $75 price target.
Bullish indicators and price action.
Nice channel developed to trade.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。